News
09-08-2010, 10:03 PM
Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.
More... (http://www.news-medical.net/news/20100909/Cylene-Pharmaceuticals-to-report-CX-4945-inhibitor-development-at-CK2-International-Conference.aspx)
More... (http://www.news-medical.net/news/20100909/Cylene-Pharmaceuticals-to-report-CX-4945-inhibitor-development-at-CK2-International-Conference.aspx)